Quantcast
Last updated on April 24, 2014 at 5:50 EDT

Latest Typical antipsychotic Stories

2009-12-10 06:57:00

TITUSVILLE, N.J., Dec. 10 /PRNewswire/ -- Treatment with once-monthly INVEGA® SUSTENNA(TM) is not inferior to treatment with bi-weekly RISPERDAL® CONSTA®, according to new data from a comparative study of both treatments in patients with schizophrenia. Results of the 13-week clinical trial were released this week. An estimated one percent of the world's population suffers from schizophrenia - a brain disorder that impairs a person's...

2009-12-02 07:00:00

WALTHAM, Mass., Dec. 2 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that generic erosion of several established branded atypical antipsychotics will cause the schizophrenia drug market to decrease from $6.3 billion in 2008 to $5.2 billion in 2013 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. The new Pharmacor report entitled Schizophrenia finds that the...

2009-10-27 16:25:53

Many pediatric and adolescent patients who received second-generation antipsychotic medications experienced significant weight gain, along with varied adverse effects on cholesterol and triglyceride levels and other metabolic measures, according to a study in the October 28 issue of JAMA. Treatment for psychotic disorders, bipolar disorder, and nonpsychotic mental disorders for children and adolescents in the United States often includes second-generation antipsychotic medications....

2009-10-12 17:01:00

EAST HANOVER, N.J., Oct. 12 /PRNewswire-FirstCall/ -- Novartis Pharma AG has entered into an agreement for exclusive US and Canadian rights to Fanapt(TM) (iloperidone), a new oral medication that is approved by the US Food and Drug Administration (FDA) for the acute treatment of adults with schizophrenia. Novartis plans to launch Fanapt in the US in early 2010. As part of the agreement with Vanda Pharmaceuticals Inc., Novartis will have exclusive commercialization rights to the...

2009-10-12 17:00:00

ROCKVILLE, Md., Oct. 12 /PRNewswire-FirstCall/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) announced today that it has entered into an agreement with Novartis Pharma AG to commercialize and develop Fanapt(TM) (iloperidone), Vanda's anti-psychotic, in the U.S. and Canada. Fanapt(TM) was approved by the U.S. Food and Drug Administration on May 6, 2009 for the acute treatment of schizophrenia in adults. Fanapt((TM)) is a mixed dopamine D2 / serotonin 5HT2A receptor antagonist. The U.S....

2009-09-14 06:00:00

ISTANBUL, Sept. 14 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) today reported final results of a SAPHRIS(R) (asenapine) long-term schizophrenia relapse prevention clinical study. In the double-blind phase of the study, time to relapse or impending relapse, the primary efficacy endpoint, was significantly longer with SAPHRIS than with placebo (P < 0.0001). At the end of the double-blind phase, significantly fewer patients had relapsed with SAPHRIS than with...

2009-08-14 07:30:00

Schering-Plough Corporation (NYSE: SGP) today announced that the U.S. Food and Drug Administration (FDA) has approved SAPHRIS(R) (asenapine) sublingual tablets for acute treatment of schizophrenia in adults and acute treatment of manic or mixed episodes associated with bipolar I disorder with or without psychotic features in adults. SAPHRIS can be used as a first-line treatment and is the first psychotropic drug to receive initial approval for both of these indications simultaneously....

2009-08-14 06:00:00

KENILWORTH, N.J., Aug. 14 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) today announced that the U.S. Food and Drug Administration (FDA) has approved SAPHRIS((R)) (asenapine) sublingual tablets for acute treatment of schizophrenia in adults and acute treatment of manic or mixed episodes associated with bipolar I disorder with or without psychotic features in adults. SAPHRIS can be used as a first-line treatment and is the first psychotropic drug to receive initial...

2009-07-30 06:30:30

Older diabetic patients who take antipsychotic medications appear to have an increased risk of hospitalization for hyperglycemia (elevated blood glucose level), especially soon after beginning treatment, according to a new report. The antipsychotic drugs prescribed for older adults with dementia may be associated with adverse effects, including Parkinson's disease symptoms, stroke and diabetes. "The risk of diabetes may be partly related to chronic effects of the weight gain associated with...

2009-05-19 13:56:00

SAN FRANCISCO, May 19 /PRNewswire/ -- New data demonstrate that maintenance therapy with RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Treatment (RLAT) significantly delayed the time to relapse compared to placebo in patients with Bipolar I Disorder. Results of the study were presented this week at a major medical meeting. Bipolar Disorder is a brain disorder that causes unusual shifts in a person's mood, energy and ability to function. It is often characterized by debilitating mood...